NEW YORK, Dec. 2 (GenomeWeb News) - Transgenomic today said that it has entered into "several specific agreements" with Novartis Pharmaceuticals to provide mutation discovery services to support translational research programs in oncology.
Transgenomic said that the goal of the collaboration is to support biomarker discovery efforts in clinical trials by identifying genetic mutations that correlate with patients' response or responses to cancer therapeutics. Transgenomic said it has already performed proof-of-principle work and begun to deliver data for the projects.
The companies have several specific project agreements, according to Transgenomic, including a clinical assay/protocol development project.
"Novartis Oncology is dedicated to incorporating knowledge of genomic changes associated with cancer into the drug development process," said Kenneth Culver, global head of translational medicine at Novartis Oncology. He added that the company is using Transgenomic's WAVE technology to detect low-abundance mutations in clinical specimens, and to scan for mutations "rather than develop specific assays for each potential mutation."